Cargando…

Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Background: Previous studies have suggested that bile acids (BAs) may participate in the development and/or progression of metabolic dysfunction-associated steatotic liver disease (MASLD). The present study aimed to define whether specific BA molecular species are selectively associated with MASLD d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Jiaming, Luo, Ling, Zhou, Ting, Feng, Xiongcai, Ye, Junzhao, Zhong, Bihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526305/ https://www.ncbi.nlm.nih.gov/pubmed/37759756 http://dx.doi.org/10.3390/biom13091356

Ejemplares similares

Age patterns of nonalcoholic fatty liver disease incidence: heterogeneous associations with metabolic changes
por: Lin, Yansong, et al.
Publicado: (2022)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
por: Staufer, Katharina, et al.
Publicado: (2023)

Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease
por: Shao, Congxiang, et al.
Publicado: (2023)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
por: Chan, Wah-Kheong, et al.
Publicado: (2023)

The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
por: Paklar, Natasa, et al.
Publicado: (2023)

The impact of cortisol in steatotic and non‐steatotic liver surgery
por: Cornide‐Petronio, María Eugenia, et al.
Publicado: (2017)

Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis
por: Li, Fuxi, et al.
Publicado: (2021)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
por: Eskridge, Wayne, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
por: Platek, Anna E., et al.
Publicado: (2023)

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
por: Takahashi, Yoshihisa, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs
por: Zhu, Baoqiang, et al.
Publicado: (2023)

An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
por: Kendall, Timothy J., et al.
Publicado: (2023)

The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
por: Backer, Sean, et al.
Publicado: (2023)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
por: Kim, Gi-Ae, et al.
Publicado: (2023)

Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection
por: Luo, Ling, et al.
Publicado: (2022)

Impact of skeletal muscle mass evaluating methods on severity of metabolic associated fatty liver disease in non-elderly adults
por: Zhou, Ting, et al.
Publicado: (2023)

Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Luo, Ling, et al.
Publicado: (2022)

Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study
por: Liao, Xianhua, et al.
Publicado: (2022)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Mitogen Activated Protein Kinases in Steatotic and Non-Steatotic Livers Submitted to Ischemia-Reperfusion
por: Jiménez-Castro, Mónica B., et al.
Publicado: (2019)

Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts
por: Da, Ben L, et al.
Publicado: (2022)

Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials
por: Ma, Qianqian, et al.
Publicado: (2022)

The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease
por: He, Jie, et al.
Publicado: (2022)

Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers
por: Haq, Adeel, et al.
Publicado: (2023)

The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease
por: Wu, Tingfeng, et al.
Publicado: (2022)

Hepatic Gene Expression Profiles Differentiate Steatotic and Non-steatotic Grafts in Liver Transplant Recipients
por: Šeda, Ondrej, et al.
Publicado: (2019)

The Role of Neuregulin-1 in Steatotic and Non-Steatotic Liver Transplantation from Brain-Dead Donors
por: Micó-Carnero, Marc, et al.
Publicado: (2022)

The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
por: Huang, Yunqian, et al.
Publicado: (2023)

The Role of GLP1 in Rat Steatotic and Non-Steatotic Liver Transplantation from Cardiocirculatory Death Donors
por: Avalos-de León, Cindy G., et al.
Publicado: (2019)

Double-lobectomy in a steatotic liver transplantation rat model
por: Fan, Lin, et al.
Publicado: (2021)

Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease
por: Wu, Tingfeng, et al.
Publicado: (2021)

How to Preserve Steatotic Liver Grafts for Transplantation
por: Patrono, Damiano, et al.
Publicado: (2023)

Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
por: Moon, Joon Ho, et al.
Publicado: (2023)

Embracing the principles of practice transfer to get the word out on the new metabolic dysfunction-associated steatotic liver disease nomenclature
por: Carr, Rotonya M.
Publicado: (2023)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
por: Nagai, Koki, et al.
Publicado: (2023)

Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES
por: Wu, Yanrui, et al.
Publicado: (2023)

Allopurinol versus Febuxostat: A New Approach for the Management of Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
por: Al-Shargi, Amani, et al.
Publicado: (2023)

Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease
por: Ma, Qianqian, et al.
Publicado: (2021)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i635n03v9kn2c0397t66uc27ev